CFTR and cystic fibrosis: Indeed, VX-809 monotherapy has been shown to reduce sweat-chloride levels in a dose-dependent manner in F508del homozygous CF patients, but these effects were not associated with detectable improvements in airway F508del CFTR function (by nasal potential difference measurements), F508del CFTR trafficking (in rectal biopsies), or lung function [28].